Bispecific HIV-1-neutralizing antibodies
In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.
1. A bispecific antibody in a CrossMab format capable of neutralizing HIV, wherein the antibody comprises a light chain and heavy chain portion of a first antibody that binds to a HIV envelope protein, and a light chain and heavy chain portion of a second antibody ibalizumab that binds to a cell membrane receptor protein or a cell membrane co-receptor protein,
wherein the first antibody is selected from the group consisting of:
10E8.2, wherein the light chain portion of 10E8.2 comprises SEQ ID NO: 33, and the heavy chain portion of 10E8.2 comprises SEQ ID NO: 34;
10E8.2.1, wherein the light chain portion of 10E8.2.1 comprises SEQ ID NO: 33, and the heavy chain portion of 10E8.2.1 comprises SEQ ID NO: 35;
10E8.2.2, wherein the light chain portion of 10E8.2.2 comprises SEQ ID NO: 33, and the heavy chain portion of 10E8.2.2 comprises SEQ ID NO: 36;
10E8.2.3, wherein the light chain portion of 10E8.2.3 comprises SEQ ID NO: 33, and the heavy chain portion of 10E8.2.3 comprises SEQ ID NO: 37;
the light chain portion of the second antibody ibalizumab comprises an amino acid sequence identical to SEQ ID NO: 1, and the heavy chain portion of the second antibody ibalizumab comprises an amino acid sequence identical to SEQ ID NO: 2.
2. A pharmaceutical composition comprising the bispecific antibody of claim 1 , and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , wherein the composition is formulated for oral, intranasal, pulmonary, intradermal, transdermal, subcutaneous, intramuscular, intraperitoneal, or intravenous delivery.